A CHEMISTRY THAT WORKS: HOECHST MARION ROUSSEL
Article Abstract:
Hoechst Marion Roussel (HMR) has posted a sales growth of 13 percent for 1997-98. Its exports have fetched Rs1.16 billion, of which the CIS accounted for 50 percent. Its Rs650 million brand Baralgan was banned in India. It has launched Cardace (cardiac therapy), Rulide and Tarivid (anti-infectives) and Rotane (gastro- enterology product). HMR and Ranbaxy are jointly promoting products like Tarivid, Rotane and Zanocin. HMR has cut down its workforce by 30 percent to 2,200 in the past four years. In 1998- 99, the workforce will be further reduced to 2,000. The company has closed its facility at Thane and its brands are being sourced through contract manufacturing. HMR launched a rifampicin based formulation in 1996-97. It has transferred its facility at Ankleshwar to its joint venture with Chiron Corp. It has a facility at Mulund, Mumbai. Its third facility at Verna in Goa is likely to commence production by the end of 1999. HMR has 66.67 percent stake in Roussel India and plans to buy the balance stake at Rs323.09 per share. (rk) --------------------------------------------------------- Financial Performance of Hoechst Marion Roussel (Rs in million) --------------------------------------------------------- Particulars 1999 1998 1997 (projected) --------------------------------------------------------- Sales 6,444.00 3,825.00 3,869.00 --------------------------------------------------------- Net profit 337.00 310.00 211.00 --------------------------------------------------------- EPS (Rs) 14.60 13.50 9.20 ---------------------------------------------------------
Comment:
Posts sales growth of 3% for 1997-98, with exports reaching Rs1.16 bil
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
INFAR TO INVEST Rs100 Cr, PLANS MANUFACTURING UNIT
Article Abstract:
Infar (India) Limited, Calcutta, a subsidiary of $13 billion Dutch pharmaceutical giant, Akzo Nobel, plans to invest Rs100 crore in the next five years. A new manufacturing unit is likely to be commissioned by 2002 AD at Calcutta. About 50 percent of the capital would be pumped into the new unit to make hormonal and ordinary tablets, ampoules, sachets, and capsules among other dosage forms. Organon, the pharmaceutical unit of Akzo Nobel, plans to launch Sandrena, a hormonal replacement therapy for women shortly. Organon pioneered oestrogen extract in the 1920s and testosterone in 1935. A safe, new contraceptive pill has been launched and clinical trials of a contraceptive ring are underway. Organon spends about $25 million on R&D. (nr)
Comment:
Infar (India) Limited, Calcutta, a subsidiary of $13 billion Dutch pharmaceutical giant, Akzo Nobel, plans to invest Rs100 crore in the next five years.
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
PRICE HIKE WILL BENEFIT ONLY DR REDDY's
Article Abstract:
The decision to increase prices of 23 formulations by the National Pharmaceutical Pricing Authority (NPPA) is likely to benefit only Dr Reddy's Laboratories. The price hike is marginal for formulations which from a major part of the turnover. Prices of ibuprofen combination with paracetamol produced by Dr Reddy's Labs has been hiked by 12.50 percent. The price has gone up from Rs2.40 to Rs2.70. Ibuprofen is a major contributor to the company's turnover. Dr Reddy's was also the first to develop the process technology for ibuprofen. (uh)
Comment:
Decision by NPPA to increase prices of 23 formulations likely to benefit the firm
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A CHEMISTRY THAT WORKS: CIPLA CIPLA, ORCHID CAN EXPORT VIAGRA CLONE CIPLA SET TO HIT INDIANS WITH DESI VIAGRA
- Abstracts: PETRONET PLANNING TO RAISE Rs12,300 CR IN TWO YEARS BETZDEARBORN PLANS TO PUMP Rs12.5 Cr INTO NEW FACILITY AIG TO INVEST $25 M IN PETRONET VIA EQUITY
- Abstracts: SYNDICATE BANK EYES Rs850-CR HOUSING LOAN DISBURSALS HDFC SLASHES INTEREST RATES FOR HOUSING LOANS. SYNDICATE BANK TO TIE UP WITH CONSUMER LOANS COS
- Abstracts: ANCO COMMUNICATIONS LIMITED TTL TO LAUNCH OPERATIONS IN HYDERABAD SOON
- Abstracts: ZURICH INTL TO DIVEST 20% IN INDIAN ARM WITHIN 3 YEARS GIC PLANS TO CUT RELIANCE ON GLOBAL REINSURANCE. `ALL FOUR GIC OUTFITS SHOULD BE MERGED INTO PARENT'